| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 614.1 | 453.4 | 400.2 |
| Other income | 4.1 | 3.8 | 2.9 |
| Total income | 618.3 | 457.2 | 403.1 |
| Profit before exceptional items & tax | 31.8 | 31.3 | 27.9 |
| Profit before tax | 31.8 | 31.3 | 27.9 |
| Net profit | 24.7 | 24.6 | 21.6 |
| Operating margin | 5.1% | 6.8% | 6.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.40% |
|---|---|
| Net profit, quarter on quarter | +0.40% |
| Revenue, year on year | +53.40% |
| Operating profit, year on year | +10.80% |
| Operating profit, quarter on quarter | +0.70% |
NSE results filing, NSE: REMUS. Figures extracted from the filing.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹855.00
- Market cap
- ₹1,008 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 27.2×Sector 47.2×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.